Swiss Biotech Giant Roche Announces $50 Billion Investment in US Manufacturing and R&D
Basel, Switzerland – Roche, a leading biotechnology company, has announced plans to invest $50 billion in the United States over the next five years. The investments will strengthen its existing presence in the country, with 13 manufacturing sites and 15 research and development (R&D) facilities across the Pharmaceutical and Diagnostics Divisions.
The investment is expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities. This will increase Roche’s existing workforce of over 25,000 employees in 24 sites across eight US states.
Roche CEO Thomas Schinecker stated that the investments underscore the company’s long-standing commitment to research, development, and manufacturing in the US. The company has a 110-year legacy in the US, which has driven jobs, innovation, and intellectual property creation.
The investment will lay the foundation for Roche’s next era of innovation and growth, benefiting patients in the US and around the world. Once all new manufacturing capacity comes online, Roche is expected to export more medicines from the US than it imports, further increasing its market presence.
Roche has a long history of prioritizing sustainability, with over 125 years of commitment to reducing its environmental impact. The company aims to achieve net zero emissions by 2045 and has set ambitious targets for scientific excellence and innovation.
This significant investment is a testament to Roche’s dedication to its US operations and its commitment to driving growth, innovation, and job creation in the country.
Source: https://www.roche.com/media/releases/med-cor-2025-04-22